Moleculin Biotech, Inc. (MBRX) earnings
MBRX earnings moved a median of -1.18% by the close. Quarterly and annual MBRX reports and results, each read against the price at its own news timestamp. Back to the MBRX overview →
26 measured MBRX earnings events.
Where these MBRX earnings landedvs 26 measured MBRX earnings reactions
| Middle 50% of MBRX earnings reactions | -3.56% to +0.72% |
|---|---|
| Median reaction (to close) | -1.18% |
| Measured reactions | 26 |
Point-in-time · zero look-ahead
Half of the 26 MBRX earnings events with a measured close landed between -3.56% and +0.72%; 31% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial | Press release | -1.67% | +2.03% | |
| Form 10-Q Moleculin Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.67% | +2.03% | |
| Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial | Press release | -5.09% | -2.31% | |
| Form 10-Q Moleculin Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | -5.09% | -2.31% | |
| Form 10-K/A Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.67% | +0.00% | |
| Form 10-K Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.84% | -0.96% | |
| Moleculin Reports Second Quarter 2025 Financial Results and Highlights | Press release | -2.98% | +0.72% | |
| Form 10-Q Moleculin Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.98% | +0.72% | |
| Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | -2.65% | |
| Form 10-Q Moleculin Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.65% | |
| Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast | Press release | +2.02% | +0.92% | |
| Form 10-K/A Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.34% | -3.81% | |
| Form 10-K/A Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.71% | +9.22% | |
| Form 10-K Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.86% | -4.50% | |
| Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -3.54% | -1.18% | |
| Form 10-Q Moleculin Biotech, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.54% | -1.18% | |
| Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast | Press release | +2.19% | +1.25% | |
| Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.60% | +0.00% | |
| Form 10-Q Moleculin Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.60% | +0.00% | |
| Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | -4.69% | |
| Form 10-Q Moleculin Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -4.69% | |
| Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast | Press release | — | -6.75% | |
| Form 10-K/A Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +4.38% | |
| Form 10-K Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.81% | -12.50% | |
| Form 10-Q Moleculin Biotech, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.27% | -3.56% | |
| Moleculin Reports Third Quarter 2023 Financial Results | Press release | -1.27% | -3.56% |
Keep exploring
More MBRX: analyst actions → · SEC filings → · MBRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) | 427 | -0.21% | 39% |
| Veracyte, Inc. (VCYT) | 427 | -0.15% | 46% |
| Summit Therapeutics Inc. (SMMT) | 426 | +0.03% | 50% |
| Scholar Rock Holding Corporation (SRRK) | 425 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.